Investors in Capricor Therapeutics Have a Chance to Lead Fight in Securities Fraud Case
Investors in Capricor Therapeutics Have a Chance to Lead Fight in Securities Fraud Case
The Rosen Law Firm, which specializes in protecting investor rights, has announced a class action lawsuit for investors who purchased shares of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025, and July 26, 2026. This case could provide a vital opportunity for investors to reclaim losses and seek justice against misleading practices by the company's executives.
Overview of the Lawsuit
The lawsuit highlights several serious allegations against Capricor and its management, including claims that the defendants made materially false statements and failed to disclose essential information about the company's leading product, Deramiocel—a cell therapy aimed at treating Duchenne muscular dystrophy (DMD). Among the significant points raised:
1. Change in Analysis Plan: It is claimed that Capricor altered the pre-specified statistical analysis plan used to assess clinical data for Deramiocel without prior approval from the FDA.
2. Regulatory Risk: As a result of these undisclosed changes, the FDA was informed of a significant risk that the clinical data might not substantiate claims of Deramiocel's effectiveness.
3. Misleading Information: The suit contends that the positive statements made by the company regarding its business outlook were misleading and not based on reasonable evidence.
When these details became public, the stock's value dropped sharply, leaving investors suffering considerable financial damage.
How to Participate
If you are an investor who bought shares during the specified period, you may be eligible to join the class action lawsuit. Interested individuals can join the movement by:
- - Visiting the Rosen Law Firm's dedicated page at rosenlegal.com
- - Calling Phillip Kim, Esq. at their toll-free number: 866-767-3653
- - Emailing for more information at [email protected]
Potential lead plaintiffs need to file a motion with the Court by September 28, 2026. This status assists in strategizing the case and representing fellow investors effectively.
Why Choose Rosen Law Firm
The Rosen Law Firm has an impressive track record in handling securities class actions and derivative litigation. Their history of achieving significant settlements, such as the largest securities class action settlement against a Chinese firm, demonstrates their effectiveness as a leader in this legal arena.
Founded by Laurence Rosen, an esteemed attorney recognized as a Titan of the Plaintiffs’ Bar, the firm emphasizes quality representation and possesses a vast resource network to ensure comprehensive support for victims of securities fraud. They were ranked first for the number of securities class action settlements in 2017 and have recovered billions for investors over recent years.
Final Thoughts
No class has yet been certified in this case, meaning that engaged investors are urged not to take a passive role. Choosing qualified legal counsel can help protect your interests as the class action progresses. Regardless of whether you opt to serve as a lead plaintiff or remain a passive participant, understanding your rights and opportunities is crucial during this recovery process. Make sure to stay informed and use your voice through this legal avenue, potentially leading to significant financial recovery.
For the latest updates, follow the Rosen Law Firm on their social media platforms, including LinkedIn, Twitter, and Facebook.
This article is meant for informational purposes only and does not constitute legal advice.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.